Paper Details

  1. Home
  2. Paper Details

Disseminated fungal infection in a patient receiving zanubrutinib.

Author: BallasZuhair, SanchezRolando, WalshMadalyn, XuAlice

Case ReportsIn the medical field, a report that describes in detail a unique case, an unusual medical condition, or the effect of a treatment. Provides new insights and possibilities for treatment through individual patient cases.

Overview

This case report describes a fatal case of disseminated aspergillosis in a patient receiving zanubrutinib, a Bruton's tyrosine kinase inhibitor. This case highlights the potential immunosuppressive effects of zanubrutinib and emphasizes the importance of recognizing and managing infection risks in patients on this medication.
Paper Details　
Original Abstract of the Article :
We report a case of fatal disseminated aspergillosis in the setting of administration of zanubrutinib, a second-ge...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10264913/

データ提供：米国国立医学図書館（NLM）

Zanubrutinib and Fungal Infections: An Unexpected Desert Storm

The use of targeted therapies, like zanubrutinib, has revolutionized the treatment of various cancers, offering hope for patients battling these formidable diseases. However, like a sudden desert storm, unexpected side effects can arise, presenting challenges to clinicians and patients alike. This case report describes a fatal disseminated aspergillosis in a patient receiving zanubrutinib, highlighting a potential risk associated with this otherwise promising medication.

Zanubrutinib and Fungal Infections: A Desert Mystery

This case report presents a troubling observation, raising concerns about the potential for zanubrutinib to increase the risk of disseminated fungal infections. The authors highlight the need for further research to understand the mechanisms behind this side effect and to develop strategies for mitigating its occurrence. This case underscores the importance of careful monitoring and prompt intervention in patients receiving zanubrutinib, particularly those with underlying immunosuppression.

Navigating the Desert of Cancer Treatment

The landscape of cancer treatment is constantly evolving, with new therapies emerging and new challenges arising. This case report serves as a reminder that even the most promising medications can have unexpected side effects. By remaining vigilant and embracing a proactive approach, clinicians can navigate the complexities of cancer treatment and ensure the best possible outcomes for their patients.

Dr. Camel's Conclusion

This case report is like a sudden sandstorm in the vast desert of cancer treatment, highlighting an unexpected risk associated with zanubrutinib. The researchers provide a stark reminder of the unpredictable nature of medical treatments and emphasize the importance of careful monitoring and vigilance in clinical practice. This case underscores the ongoing need for research to understand the complex interactions between medications and the human body, ensuring the safety and well-being of patients in the ever-evolving landscape of medical care.
Date :
  1. Date Completed n.d.
  2. Date Revised 2023-06-19
Further Info :

Pubmed ID

37323284

DOI: Digital Object Identifier

PMC10264913

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.